Sign Out
Xarelto is contraindicated in patients with hypersensitivity to rivaroxaban or any excipient of the tablet (see 'Description').
Xarelto is contraindicated in patients with clinically significant active bleeding (e.g., intracranial bleeding, gastrointestinal bleeding).
Xarelto is contraindicated in patients with hepatic disease which is associated with coagulopathy leading to a clinically relevant bleeding risk.
Safety and efficacy of Xarelto have not been established in pregnant women. Animal data show that rivaroxaban crosses the placental barrier. Therefore use of Xarelto is contraindicated throughout pregnancy (see 'Use in Pregnancy & Lactation').
Safety and efficacy of Xarelto have not been established in nursing mothers. Animal data indicate that rivaroxaban is secreted into breast milk. Therefore Xarelto may only be administered after breastfeeding is discontinued (see 'Use in Pregnancy & Lactation').
Continue with Google